The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous The Experience of the BODE Cohort

被引:169
作者
Casanova, Ciro [1 ,2 ]
de Torres, Juan P. [3 ]
Aguirre-Jaime, Armando [2 ]
Pinto-Plata, Victor [4 ]
Marin, Jose M. [5 ]
Cordoba, Elizabeth [2 ]
Baz, Rebeca [2 ]
Cote, Claudia [6 ]
Celli, Bartolome R. [4 ]
机构
[1] Hosp Univ La Candelaria, Dept Pulm, Tenerife, Spain
[2] Hosp Univ La Candelaria, Res Unit, Tenerife, Spain
[3] Univ Navarra Clin, Pamplona, Spain
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Hosp Miguel Servet, Zaragoza, Spain
[6] Bay Pines VA Hlth Care Syst, St Petersburg, FL USA
关键词
chronic obstructive pulmonary disease; disease progression; FEV1; BODE index; longitudinal studies; AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; NATURAL-HISTORY; DECLINE; INDEX; COPD; DIAGNOSIS; SMOKING; MASS;
D O I
10.1164/rccm.201105-0831OC
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Rationale: Chronic obstructive pulmonary disease (COPD) is thought to result in rapid and progressive loss of lung function usually expressed as mean values for whole cohorts. Objectives: Longitudinal studies evaluating individual lung function loss and other domains of COPD progression are needed. Methods: We evaluated 1,198 stable, well-characterized patients with COPD (1,100 males) recruited in two centers (Florida and Tenerife, Spain) and annually monitored their multidomain progression from 1997 to 2009. Patients were followed for a median of 64 months and up to 10 years. Their individual FEV1 (L) and BODE index slopes, expressed as annual change, were evaluated using regression models for repeated measures. A total of 751 patients with at least three measurements were used for the analyses. Measurements and Main Results: Eighteen percent of patients had a statistically significant FEV1 slope decline (-86 ml/yr; 95% confidence interval [CI], -32 to -278 ml/yr). Higher baseline FEV1 (relative risk, 1.857; 95% CI, 1.322-2.610; P < 0.001) and low body mass index (relative risk, 1.071; 95% CI, 1.035-1.106; P < 0.001) were independently associated with FEV1 decline. The BODE index had a statistically significant increase (0.55, 0.20-1.37 point/yr) in only 14% of patients and these had more severe baseline obstruction. Concordance between FEV1 and BODE change was low (kappa Cohen, 16%). Interestingly, 73% of patients had no significant slope change in FEV1 or BODE. Only the BODE change was associated with mortality in patients without FEV1 progression. Conclusions: The progression of COPD is very heterogeneous. Most patients show no statistically significant decline of FEV1 or increase in BODE. The multidimensional evaluation of COPD should offer insight into response to COPD management.
引用
收藏
页码:1015 / 1021
页数:7
相关论文
共 31 条
[1]
Characterisation of COPD heterogeneity in the ECLIPSE cohort [J].
Agusti, Alvar ;
Calverley, Peter M. A. ;
Celli, Bartolome ;
Coxson, Harvey O. ;
Edwards, Lisa D. ;
Lomas, David A. ;
MacNee, William ;
Miller, Bruce E. ;
Rennard, Steve ;
Silverman, Edwin K. ;
Tal-Singer, Ruth ;
Wouters, Emiel ;
Yates, Julie C. ;
Vestbo, Jorgen .
RESPIRATORY RESEARCH, 2010, 11
[2]
LUNG-FUNCTION TESTING - SELECTION OF REFERENCE VALUES AND INTERPRETATIVE STRATEGIES [J].
不详 .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1202-1218
[3]
Smoking and lung function of lung health study participants after 11 years [J].
Anthonisen, NR ;
Connett, JE ;
Murray, RP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (05) :675-679
[4]
EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[5]
AN OVERVIEW OF OBSTRUCTIVE LUNG-DISEASES [J].
BURROWS, B .
MEDICAL CLINICS OF NORTH AMERICA, 1981, 65 (03) :455-471
[6]
The 6-min walking distance: long-term follow up in patients with COPD [J].
Casanova, C. ;
Cote, C. G. ;
Marin, J. M. ;
de Torres, J. P. ;
Aguirre-Jaime, A. ;
Mendez, R. ;
Dordelly, L. ;
Celli, B. R. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (03) :535-540
[7]
CASANOVA C, 2010, EUR RESPIR J, V36, pS44
[8]
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study [J].
Celli, Bartolome R. ;
Thomas, Nicola E. ;
Anderson, Julie A. ;
Ferguson, Gary T. ;
Jenkins, Christine R. ;
Jones, Paul W. ;
Vestbo, Jorgen ;
Knobil, Katharine ;
Yates, Julie C. ;
Calverley, Peter M. A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (04) :332-338
[9]
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946
[10]
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease [J].
Celli, BR ;
Cote, CG ;
Marin, JM ;
Casanova, C ;
de Oca, MM ;
Mendez, RA ;
Pinto Plata, V ;
Cabral, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :1005-1012